Specifically, they found overexpressing ACSL4 reduces the cytotoxic effect of tamoxifen in MCF-7 and SKBr-3, suggesting inhibiting ACSL4 could overcome tamoxifen resistance in breast cancer [54]. This evidence concerns the gene ACSL4 and breast carcinoma.